



HAL
open science

Summative Interaction Between Astaxanthin, Ginkgo biloba Extract (EGb761) and Vitamin C in Suppression of Respiratory Inflammation: A comparison with Ibuprofen

David Haines, Balazs Varga, Istvan Bak, Bela Juhasz, Fadia Fouad Mahmoud, Hejbatullah Kalantari, Rudolf Gesztelyi, Istvan Lekli, Attila Czompa, Arpad Tosaki

► To cite this version:

David Haines, Balazs Varga, Istvan Bak, Bela Juhasz, Fadia Fouad Mahmoud, et al.. Summative Interaction Between Astaxanthin, Ginkgo biloba Extract (EGb761) and Vitamin C in Suppression of Respiratory Inflammation: A comparison with Ibuprofen. *Phytotherapy Research*, 2010, 25 (1), pp.128. 10.1002/ptr.3160 . hal-00599826

HAL Id: hal-00599826

<https://hal.science/hal-00599826>

Submitted on 11 Jun 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Summative Interaction Between Astaxanthin, Ginkgo biloba Extract (EGb761) and Vitamin C in Suppression of Respiratory Inflammation: A comparison with Ibuprofen

| | |
|-------------------------------|--|
| Journal: | <i>Phytotherapy Research</i> |
| Manuscript ID: | PTR-09-0458.R3 |
| Wiley - Manuscript type: | Full Paper |
| Date Submitted by the Author: | 12-Feb-2010 |
| Complete List of Authors: | Haines, David; University of Connecticut, Molecular & Cell Biology Varga, Balazs; University of Debrecen, Pharmacology Bak, Istvan; University of Debrecen, Pharmacology Juhasz, Bela; University of Debrecen, Pharmacology Mahmoud, Fadia; Kuwait University, Medical Laboratory Sciences Kalantari, Hejbatullah; Ahvaz Jundishapur University of Medical Sciences, Pharmacology and Toxicology Gesztelyi, Rudolf; University of Debrecen, Pharmacology Lekli, Istvan; University of Debrecen, Pharmacology Czompa, Attila; University of Debrecen, Pharmacology Tosaki, Arpad; University of Debrecen, Pharmacology |
| Keyword: | Inflammation, Ibuprofen, Astaxanthin, Ginkgolide, cAMP, cGMP |
| | |



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Summative Interaction Between Astaxanthin, *Ginkgo biloba* Extract (EGb761) and Vitamin C in Suppression of Respiratory Inflammation: A Comparison with Ibuprofen

David D. Haines^{1,2}, Balazs Varga¹, Istvan Bak¹, Bela Juhasz¹, Fadia F. Mahmoud³, Hejbatullah Kalantari⁴, Rudolf Gesztelyi¹, Istvan Lekli¹, Attila Czompa¹, Arpad Tosaki¹

¹*Department of Pharmacology, Faculty of Pharmacy, University of Debrecen, Debrecen, Hungary*

²*Department of Molecular and Cell Biology, University of Connecticut, Storrs CT USA*

³*Department of Medical Laboratory Sciences, Faculty of Allied Health Sciences, Kuwait University, Kuwait*

⁴*School of Pharmacy, Department of Pharmacology and Toxicology, Ahvaz Jundishapur University of Medical Sciences, Iran*

Short Title: Phytochemicals cooperatively suppress inflammation.

Correspondence:

Prof. Arpad Tosaki, Ph.D., D.Sc.
Dept. Pharmacology, Medical Health Science Center
Faculty of Pharmacy
University of Debrecen
Nagyerdei krt. 98
4032-Debrecen
Hungary

TEL: +36-52-255-586,
FAX: +36-52-255-586
E-mail: tosaki@king.pharmacol.dote.hu

Sponsor's information: This study was supported by grants from OTKA 72315, OTKA 78223, GVOP-3.2.1.-2004-04-0269/3.0, TAMOP-4.2.2-08/1-2008-0007, and TAMOP-4.2.1.B-09/1

ABSTRACT

Here, combinations of *Ginkgo biloba* leaf extract (EGb761) plus the carotenoid antioxidant astaxanthin (ASX) and vitamin C are evaluated for summative dose effect in inhibition of asthma-associated inflammation in asthmatic Guinea Pigs. Ovalbumin-sensitized Hartley Guinea pigs challenged with ovalbumin aerosol to induce asthma, were administered EGb761, ASX, vitamin C, or ibuprofen. Following sacrifice, Bronchoalveolar lavage (BAL) fluid was evaluated for inflammatory cell infiltrates and lung tissue cyclic nucleotide content. Each parameter measured was significantly altered to a greater degree by drug combinations, than by each component acting independently. An optimal combination was identified that included astaxanthin (10 mg/kg), vitamin C (200 mg/kg), and EGb761 (10 mg/kg), resulting in counts of eosinophils and neutrophils each 1.6-fold lower; macrophages 1.8-fold lower, cAMP 1.4-fold higher; and cGMP 2.04-fold higher than levels in untreated, asthmatic animals ($p < 0.05$). In conclusion, EGb761, ASX and vitamin C are shown here to interact summatively to suppress inflammation with efficacy equal to or better than ibuprofen, a widely used non-steroidal anti-inflammatory drug (NSAID). Such combinations of non-toxic phytochemicals constitute powerful tools for prevention of onset of acute and chronic inflammatory disease if consumed regularly by healthy individuals; and may also augment effectiveness of therapy for those with established illness.

Key words: Inflammation, Astaxanthin, Ginkgolide, ibuprofen, cAMP, cGMP.

INTRODUCTION

This report describes progress toward creation of dietary phytochemical formulations (“functional foods”) containing bioactive components that interact summatively to strengthen host immunoregulatory mechanisms which prevent inflammation from becoming pathological; and augment drug therapies for age-related illnesses such as arthritis, cardiovascular syndromes, dementia, autoimmunity and many other severe conditions with underlying inflammatory pathogenesis. The products are designed to mediate therapeutic and preventive clinical outcomes equivalently or superior to commonly-used non-steroidal anti-inflammatory drugs (NSAIDs), immunosuppressants, corticosteroids and other pharmaceuticals, but with negligible adverse effects and at low cost to patients. Beyond their medical use it is anticipated that such products may be consumed for general health as food supplements and additionally provide protection against debilitating effects of a diverse range of illness. Here the anti-inflammatory capacity of the NSAID ibuprofen is compared with formulations incorporating three naturally-occurring products: the dietary carotenoid astaxanthin (ASX), *Ginkgo biloba* whole leaf extract (EGb761) and vitamin C, for the ability to independently or interactively affect major indicators of inflammatory disease severity in ovalbumin-sensitized asthmatic guinea pigs.

Asthma was used as a disease model in this study, although this disorder was not our focus. Asthma pathogenesis is a cascade of progressively severe inflammatory processes initiated by an immune imbalance (Umetsu et al. 2002) and provides a very good general paradigm for severe chronic inflammation. Moreover, the commonality of

1
2
3 signaling pathways leading to tissue damage in asthma and most other inflammatory
4 syndromes means that treatment strategies affecting major indicators of asthma-
5 associated inflammation are likely to be relevant for many conditions in which
6 inflammation plays an underlying role.
7
8
9
10
11

12 The emphasis here on general inflammatory, rather than asthma-specific
13 processes, led to the choice of ibuprofen for comparison with the other agents in the
14 context of anti-inflammatory potency. Ibuprofen is a widely-used NSAID that acts by
15 strong inhibition of cyclooxygenases (COX), enzymes which metabolize membrane
16 phospholipids into mediators called prostanoids, small molecules regulating a diverse
17 range of homeostatic functions including inflammation (Soberman and Christmas 2003).
18 The drug acts on both major isoforms of the enzyme: COX-1 which is constitutively
19 expressed in most cells and acts to protect tissues such as lining of small airways and the
20 gastrointestinal tract (Chandrasekharan et al. 2002; Soberman and Christmas 2003;
21 Warner and Mitchell 2002); and an inducible variant, COX-2, responsible for production
22 of inflammatory mediators in macrophages, neutrophils and other cells participating in
23 inflammation (Grosser 2009).
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 Ibuprofen has clinical utility in many diseases for which inflammation is a
42 major component (Hawkey 2001; Wallace 1999) and therefore, serves as a valuable
43 benchmark against which the therapeutic potential of other NSAIDs may be compared.
44 However, unlike the phytochemical products used in these experiments, ibuprofen cannot
45 be administered long-term as prophylaxis against inflammatory disease owing to its
46 toxicity (Bjarnason 2007; Moore 2007). For this reason, formulations with anti-
47 inflammatory potency in the same range as ibuprofen, but without adverse side effects,
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 constitute extremely valuable prophylaxes and therapy for persons at-risk of, or
4
5 diagnosed with illness such as asthma, allergies, arthritis and other chronic inflammatory
6
7 conditions.
8
9

10
11 Activation of many cell types during inflammation typically results in a cascade
12
13 of processes in which autocrine and paracrine expression of platelet activating factor
14
15 (PAF) is a major event. This molecule interacts with PAF receptors (PAFR) to cause
16
17 release of cytosolic calcium from cellular stores, constituting a positive feedback process
18
19 that amplifies immune cell activation and the severity of associated inflammatory
20
21 pathologies (Asako et al. 1992; Sasakawa et al. 2000; Wenzel-Seifert and Seifert 1993).
22
23 Compounds in Ginkgo extract (ginkgolides) that block PAFR thereby inhibiting increases
24
25 of intracellular calcium, interrupt this process (Brochet et al. 1999), thereby allowing
26
27 lower doses of drug to suppress calcium-dependent activation events resulting in
28
29 enhanced therapeutic outcomes (Bagnis et al. 1996; Brochet et al. 1999; Haines et al.
30
31 2000).
32
33
34
35

36
37 The present investigation builds on previous work by the authors demonstrating
38
39 synergism between EGb761 and the immunosuppressant FK506 in an *ex vivo* rat heart
40
41 model (Haines et al. 2000); and between ASX and Ginkgolide B (GB) a purified, PAFR-
42
43 inhibitory ginkgolide, in a cultured human peripheral blood mononuclear cell (PBMC)
44
45 model (Mahmoud et al. 2002; Mahmoud et al. 2004). Neither ASX nor EGb761 are
46
47 independently potent enough to be used as stand-alone treatment of serious inflammatory
48
49 disease. However, it is here hypothesized that both compounds summate when co-
50
51 administered, to mediate therapeutic effects in the same range as currently available
52
53 single-molecule drugs, with ibuprofen used in these experiments as a comparative model.
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The therapeutic effects of ginkgolides are due substantially to their ability to block PAF-PAFR-dependent calcium signaling, leading to prevention of inflammatory tissue damage (Bagnis et al. 1996; Brochet et al. 1999). ASX-mediated cytoprotection occurs through a different mechanism, involving highly efficient scavenging of toxic reactive oxygen compounds by ASX, with the additional capacity to induce host antioxidant defenses (Kang, Kim, and Kim 2001; Wang, Willen, and Wadstrom 2000). The biological action of both ginkgolides and ASX result in several common anti-inflammatory effects, including down-regulation of potentially pathological T cell activity (Mahmoud et al. 2002; Mahmoud et al. 2004). Thus, ginkgolides and ASX potentially exhibit additive and possibly synergistic interaction, an outcome seen in many drug combinations that act via different physiological pathways resulting in therapeutic benefits greater than that of each drug acting independently (Evans 2003; Haines et al. 2000; Mahmoud et al. 2002; Mahmoud et al. 2004).

MATERIALS AND METHODS

Animals (ethical background and institutional policy):

Male Hartley guinea pigs weighing between 250-350 grams and kept under pathogen-free conditions were used for all experiments in this study. Animals were maintained at the Animal Care facility at the School of Pharmacy, University of Debrecen, in Debrecen, Hungary. All activities in this study involving animal transport, care, experimentation and sacrifice have been reviewed and confirmed by University of Debrecen's committee for animal experiments. Standards of animal use demanded by this committee include an experimental design conducted on a valid scientific and ethical

1
2
3 basis, with particular attention given to animal welfare. Animal use protocols at this
4
5 institution emphasize respect and humane treatment of experimental animals, to include
6
7 three main principles: (i) Minimization of stress and discomfort (ii) Conduct non-animal
8
9 experiments where possible; and (iii) Minimization of the number of animals used to
10
11 statistically valid sample sizes.
12
13

14
15
16
17
18 *Drug administration and treatment groups:*
19

20 Pharmacological agents used for this investigation include *Ginkgo biloba* whole
21
22 leaf extract (EGb761), astaxanthin (ASX), vitamin C (Natural Alternatives International
23
24 Inc., San Marcos California, USA) and ibuprofen (Abbott Laboratories, Abbott Park
25
26 Illinois, USA) – hereafter for the purpose of brevity referred to as “drugs”. Drugs were
27
28 given orally with feed to groups of 6 animals, segregated on the basis of dosage and type
29
30 of drug. Five studies were conducted, each defined by administration of a particular drug.
31
32 The treatment groups included animals fed: (1) astaxanthin; (2) ginkgo extract/EGb761;
33
34 (3) vitamin C; (4) combinations of the previous 3 agents; and (5) ibuprofen. Controls
35
36 included one drug-free, non-asthmatic control group; and one drug-free asthmatic cohort.
37
38 Animals in both control groups were OA-sensitized and given the same feed vehicle as
39
40 treatment groups, but non-drug supplemented. One of these was subsequently challenged
41
42 with inhaled OA to induce an asthmatic response. The second received no OA challenge
43
44 and remained asthma free.
45
46
47
48
49

50 In initial studies of the effect of each agent on asthma-associated disease
51
52 indicators, independent of the action of the other drugs, guinea pigs were administered a
53
54 daily regimen of 5-200 mg astaxanthin per kg body weight; 5-100 mg/kg of ginkgo
55
56
57
58
59
60

1
2
3 extract; 50-400 mg/kg vitamin C; and various combined dosages of astaxanthin, ginkgo
4 and vitamin C. Each drug was dispersed into a suspension of 1% methylcellulose in
5 physiological saline, which was then added to standard rodent chow. Drug treatments for
6 each study covered a time period of 26 days and ran concurrently with allergen
7 sensitization (see asthmatic response induction protocol below). Animals were monitored
8 throughout the 26 day preconditioning period for any signs of adverse reaction to
9 treatments with special attention being given to unexplained death, tremors, agitation,
10 breathing difficulties, lethargy random body movements or spasms, and precipitous gain
11 or loss of weight.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

27 *Induction of Asthmatic response:*

28
29 Asthmatic responses were induced in animals by sensitization to ovalbumin (OA)
30 and subsequent aerosol challenge with this antigen by the method of Underwood *et al*,
31 and Santing *et al*, (Santing *et al*. 1992; Underwood *et al*. 1993). Briefly, each animal was
32 sensitized by intramuscular injections of 0.35 ml of a 5% (W/V) ovalbumin (OA)/saline
33 solution into each thigh on days 1 and 4 of each study. On day 25, the animals were
34 challenged with ovalbumin aerosol in a specially designed animal cage, in which the
35 guinea pigs may move freely. Habituation of each animal to the cage environment was
36 initiated 2 days before exposure to OA. Challenge with the allergen was performed by
37 inhalation of increasing aerosol concentrations containing 1.0, 3.0, 5.0 and 7.0 mg/ml
38 ovalbumin in saline for 3 min, separated by 7-min intervals. Only those animals
39 displaying prominent asthmatic symptoms were selected for further evaluation. These
40 included: i. obvious wheezing, ii. copious nasal discharge of clear, viscous fluid. Average
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 magnitude of disease indicators in animals in groups receiving ASX, EGb761, vitamin C
4
5 and combinations thereof, then was measured as described below compared with
6
7 treatment groups receiving 10-1,000 mg/kg ibuprofen per day.
8
9

10
11
12
13 *Evaluation of lung inflammatory cells:*
14

15 Animal sacrifice and collection of biological samples was conducted according to
16
17 the methods described in Underwood *et al* (Underwood et al. 1993). Briefly, twenty-four
18
19 hours after aerosol OA challenge (day 26 of each study), guinea pigs were sacrificed by
20
21 decapitation conducted rapidly to minimize pain and discomfort (a departure from the
22
23 method used by Underwood *et al*, who used cervical dislocation (Underwood et al. 1993).
24
25 Within a timeframe of no more than 8 seconds so as to prevent contamination of the
26
27 lungs with peripheral blood, the chest was opened, trachea severed directly above the
28
29 bronchi and lungs were removed and lavaged with 50 ml of DulBecco's phosphate-
30
31 buffered saline (aliquots of 10 ml), which were aspirated after gentle massage of the
32
33 organ. Bronchoalveolar lavage (BAL) fluid was collected and centrifuged at 2200 rpm
34
35 (1100 x g) for 10 min, supernatant was aspirated, and pellets were resuspended in 5 ml
36
37 0.25% NaCl to lyse residual erythrocytes. This dispersion was centrifuged at 2200 rpm
38
39 (1100 x g) for 10 min, supernatant was aspirated, and pellets were resuspended 5 ml 0.9%
40
41 NaCl. Total cell counts were done by hemocytometry using trypan blue stain. Slides were
42
43 prepared on a Shandon Cytospin 2 (Pittsburgh, PA) at 300 rpm for 5 min, fixed and
44
45 stained. Differential cell counts were performed using standard morphologic criteria to
46
47 classify cells as eosinophils, neutrophils, or macrophages, and the results were expressed
48
49 in cell numbers.
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Measurement of cAMP and cGMP:

Biopsies from lung tissues were harvested for measurement of cyclic nucleotide content. cAMP and cGMP were measured using commercially available radioimmunoassay kits (Amersham). Immediately after sampling, lung biopsies were frozen by means of a Wollenberger clamp pre-chilled in liquid nitrogen. Samples were powdered with a pestle and mortar in liquid nitrogen and trichloroacetic acid (TCA) was added to the powdered frozen samples (10 ml to every mg of tissue). Samples were further homogenized in frozen TCA using a drying mortar and then centrifuged at 14,000 x g for 10 min at 4°C. The supernatants were extracted 6 times in water-saturated diethyl ether, evaporated and assayed for cAMP and cGMP by radioimmunoassay using liquid scintillation counter (Packard, Tri-Carb 2100TR).

Dosage selection for drug combination studies:

After evaluating the changes mediated by each drug independently on BAL inflammatory cells and lung tissue cAMP and cGMP content, the effect of drug co-administration on these parameters was measured. As shown in Table 1 and Figures 1-5, three different combinations of astaxanthin, ginkgo extract and vitamin C were used to estimate the minimum dosage of each agent necessary to maximally suppress each disease-associated parameter. The dose ranges used in these studies (shown in Table 1 and Figures 1-5) was in excess of what would reasonably be expected to correspond to veterinary clinical use; and would correspond to unrealistically high dosages if scaled linearly to the average weight of a human (Feldman and McMahon 1983). However,

1
2
3 small animals with high metabolic rates typically metabolize a drug much more rapidly
4
5 than larger animals; hence the effects seen at the dosages used in this study are expected
6
7 to be reasonable predictors of the responses in humans (Feldman and McMahon 1983). In
8
9 planning these experiments it was also anticipated that response trends of disease
10
11 indicators that may be difficult to detect at lower dosage (but are nonetheless of potential
12
13 therapeutic significance), are better-defined at the dosages used here (Feldman and
14
15 McMahon 1983).
16
17
18
19
20
21

22 Statistics:

23
24 The data were expressed as the mean \pm SEM. One-way analysis of variance test was
25
26 first carried out to test for any differences between the mean values of all groups. If
27
28 differences were established, the values of the treated groups were compared with those of
29
30 the drug-free control group by multiple t-test followed by Bonferroni correction. A change
31
32 of $p < 0.05$ between the drug-free control and treated groups was considered to be significant.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

RESULTS

No unexpected deaths or other adverse effects occurred during the preconditioning period. This was somewhat surprising in the case of animals administered ibuprofen since there is toxicity associated with its chronic use (Bjarnason 2007; Moore 2007) and doses administered were high. It is likely that the animals administered this drug suffered some degree of gastrointestinal damage, however an assessment for this was not made and none of the ibuprofen-treated animals exhibited obvious adverse effects.

Following preconditioning, the 5 inflammation-associated indicators of asthma severity described above in Methods were evaluated in the treated animals and compared with outcomes in two control groups: non asthmatic guinea pigs; and a group of OA-challenged asthmatic animals that had received no drug pre-treatment. As shown in Table 1 and Figures 1-5, significant inhibition of disease indicators was observed in animals administered each product independently and in combination. Comparison of the average magnitude of indicators in treated animal groups with the untreated asthmatic group demonstrated significantly favorable effects ($p < 0.05$) of all products and their combinations in the upper dosage range tested. The indicators: levels of BAL inflammatory cell infiltrate and lung tissue cyclic nucleotide content exhibited significantly favorable dose-responsive correlation to pre-treatment of animals with ASX (Table 1A); *Ginkgo biloba* leaf extract (Table 1B); vitamin C (Table 1C); combined administration of ASX, Ginkgo and vitamin C (Table 1D); and ibuprofen (Table 1E). As shown in Figures 1-5, when compared with drug-free asthmatic controls, animals pretreated with each agent or their combinations showed significant suppression of the

1
2
3 disease severity indicators: BAL fluid inflammatory cell content (Figures 1-3); and lung
4
5 tissue cyclic nucleotides (Figures 4 and 5) ($p < 0.05$). Treatment of animals with ASX,
6
7 Ginkgo and vitamin C or their combinations resulted in suppression of each disease
8
9 indicator to the same range as ibuprofen (Table 1, Figures 1-5), demonstrating that under
10
11 the conditions of the present study, the three natural products (ASX, Ginkgo and vitamin
12
13 C) mediated an anti-inflammatory effect equal or superior to that of ibuprofen.
14
15

16
17 Summative enhancement of drug effects between ASX, EGb761 and vitamin C
18
19 was observed (Table 1) but was not an easily identified feature of the experimental
20
21 outcomes. Figures 1-5 show average magnitudes of disease indicators in treatment groups
22
23 administered the lowest dose of each agent or combination of agents significantly
24
25 different ($p < 0.05$) from the untreated asthmatic control group. At the dosages used,
26
27 average disease indicator levels in animals receiving combined treatments do not appear
28
29 obviously improved versus groups treated with single agents (Figures 1-5). Indeed,
30
31 qualitative comparison of inflammatory cell infiltrate numbers between treatment groups
32
33 shown in Figures 1-3 suggest that some of the single-agent treated groups experienced
34
35 better improvement than those treated with 10 mg/kg each of and EGb761 plus 200
36
37 mg/kg of vitamin C. Statistical analysis did however reveal significant additive
38
39 interaction between these three agents suggesting benefits to co-administration in
40
41 prevention or treatment of asthma. Animals receiving 10 mg/kg ASX (Table 1A), or 10
42
43 mg/kg EGb761 (Table 1B), or 200 mg/kg vitamin C (Table 1C), or less independently of
44
45 treatment with other agents did not exhibit BAL inflammatory cell numbers or lung tissue
46
47 cyclic nucleotide levels significantly different from asthmatic controls. However,
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 combined administration of these agents at the dosages stated, correlated with significant
4
5 improvement in all disease indicators ($p < 0.05$) (Table 1D).
6
7
8
9

10 **DISCUSSION**

11
12 The present study demonstrates that in comparison with untreated controls,
13 animals fed astaxanthin, *Ginkgo biloba* extract and vitamin C alone or in combination
14 exhibited significantly lower BAL fluid inflammatory cell numbers and enhancement of
15 lung tissue content of cAMP and cGMP (Figures 1-5). The magnitude of these anti-
16 inflammatory effects mediated by each phytonutrient product independently was
17 observed to be in the same range as outcomes in ibuprofen-treated animal groups
18 (Figures 1-5).
19
20
21
22
23
24
25
26
27
28

29 The data suggest that the anti-inflammatory effects of ASX, EGb761 and
30 vitamin C acting in concert counteracts pathological inflammation to a more significant
31 degree than any component acting independently (Table 1). Although summative
32 enhancement of drug effects was not a striking characteristic of the experimental
33 outcomes, the significantly reduced dosage of each agent needed to achieve therapeutic
34 effects when co-administered is clinically meaningful since products for human use in
35 place of, or augmenting ibuprofen may be configured to contain lower dosage of each
36 agent, thereby reducing risk of adverse reaction to persons who may be sensitive to any
37 of the three agents.
38
39
40
41
42
43
44
45
46
47
48
49

50 The independent effect of ASX, EGb761, vitamin C and ibuprofen on selected
51 disease indicators was expected based on the known mechanisms of inflammation
52 underlying the pathogenesis of asthma and the pharmacology of each of the products. The
53
54
55
56
57
58
59
60

1
2
3 highly potent free radical scavenging properties of ASX is expected to systemically
4
5 suppress the intensity of oxidative processes in ASX-treated animals. Such a shift,
6
7 particularly when it occurs in the lungs is observed to activate antioxidant/reactive
8
9 oxygen signaling processes that favorably alter major indicators of asthma and related
10
11 respiratory syndromes (Fan et al. 1998; Kirkham and Rahman 2006; Kurashige et al.
12
13 1990).

14
15
16
17 The experimental endpoints chosen for this study were selected on the basis of
18
19 their relevance to asthma-associated inflammation, which is a complex process involving
20
21 activation of cytokine networks tissue damage and many other pathological features.
22
23 Nevertheless BAL content of inflammatory cells and lung tissue cyclic nucleotide levels
24
25 are established indicators of the severity of inflammatory lung disease (Busse 1998; Hai
26
27 2007; Hamad et al. 2003; Underwood et al. 1993; Wenzel 1996) and changes in the
28
29 magnitude of these indicators provide a simple and direct picture of the effectiveness of a
30
31 particular therapy.
32
33
34
35

36
37 The ability of EGb761 to mediate the same favorable changes in major disease
38
39 indicators as ASX is most likely due primarily to components of the mixture that block
40
41 the PAF receptor, principally the terpene trilactones such as ginkgolide B (GB) (Bagnis et
42
43 al. 1996; Brochet et al. 1999). Systemic inhibition of PAF-dependent processes is
44
45 expected to interrupt the pathogenesis of asthma at several checkpoints. Of particular
46
47 importance is the probable effect on pathogenic T lymphocytes that act as triggers for the
48
49 disease. These cells express high levels of IL-5 which act in an autocrine and paracrine
50
51 manner to induce expression of PAF and its cognate receptor on T cells, inflammatory
52
53 cells and several other categories of tissue involved in asthmatic inflammation
54
55
56
57
58
59
60

1
2
3 (Calabresse et al. 1992). PAF thus acts as an amplifier of a wide range of inflammation-
4 associated processes (Calabresse et al. 1992), hence blockade of its receptor is expected
5 to significantly attenuate the two major indicators of disease studied here, and a host of
6 others. Other components of EGb761 undoubtedly also contributed to the observed
7 effects. *Ginkgo biloba* leaf extract, contains bioflavones which inhibit COX-2 and
8 cAMP-phosphodiesterase (Saponara and Bosisio 1998), the latter property possibly
9 acting as a contributor to EGb761's ability to enhance cyclic nucleotide levels in lung
10 tissue. Here cAMP and cGMP content of lung tissue were evaluated as asthma-associated
11 biomarkers, reflecting efficacy of drug treatments. This is a consequence of the role of
12 both cAMP and cGMP as second messengers in airway smooth muscle cells (SMC) that
13 act to decrease contractility thus relaxing the airways and contributing to lessening of
14 disease severity (Hai 2007; Hamad et al. 2003; Underwood et al. 1993). It is therefore
15 likely that phosphodiesterase inhibitors present in EGb761 contributed to anti-
16 inflammatory effects by preservation or enhancement of SMC cyclic nucleotide levels.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

36 Vitamin C was included in our formulations as a water-soluble dietary
37 antioxidant, expected to act as a physiologic relay, allowing scavenging and urinary
38 elimination of reactive oxygen metabolites. It has been shown to augment the activity of
39 astaxanthin in suppression of oxidative damage secondary to *helicobacter pylori* infection
40 (Wang, Willen, and Wadstrom 2000), a result which suggested it would interact well with
41 ginkgolides and astaxanthin in suppression of asthma-associated inflammation.
42
43
44
45
46
47
48
49

50 The decision to use ibuprofen as a reference drug against which to compare the
51 anti-inflammatory capacities of the other agents was made with some reservation. Its
52 therapeutic properties are due substantially to its ability to strongly inhibit COX-2.
53
54
55
56
57
58
59
60

1
2
3 However, the compound also inhibits COX-1, a feature which contributes to dysregulated
4 platelet aggregation and gastric damage (Kakuta et al. 2008; Rao and Knaus 2008). COX-
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 inhibition additionally promotes bronchoconstriction in asthmatics (Harrington et al. 2008), thereby contributing to lung inflammation and potentially adding a built-in confounder to the study given the use of an asthma model. Rofecoxib (brand name Vioxx) was also considered for use as a reference drug, since as a strongly anti-inflammatory, specific inhibitor of COX-2, with no associated effect on COX-1 (Kose et al. 2009) it was expected to favorably alter asthma inflammation-associated indicators without counteracting these outcomes through exacerbation of the disease process. Two other COX-2 selective NSAIDs, celecoxib (brand name Celebrex) and valdecoxib (brand name Bextra) were also considered for use in the study.

Although Vioxx, Celebrex, Bextra or other COX-2-selective NSAIDs would have been more appropriate to our model, using any of these as a reference drug would not have been consistent with the major aim of this research, which is to compare the anti-inflammatory capacity of phytochemical formulations that may be consumed regularly for general health, with a widely used NSAID that can be taken only for brief periods as a therapeutic measure. The three aforementioned drugs are associated with occurrence of serious, potentially lethal side effects (Chan et al. 2009; Dajani and Islam 2008; El et al. 2009; Ray 2009) and only Celebrex remains in clinical use, making them irrelevant to the aims of this study due to their very limited use in healthcare. Anti-asthmatic drugs were likewise not considered for the present investigation since the objective was not to develop an asthma-specific therapy, but establish groundwork for a phytochemical-based NSAID with clinical application in multiple disorders.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Ultimately it was decided that the advantages of ibuprofen outweighed its drawbacks. The drug is available without prescription, is one of the most widely-used anti-inflammatory compounds ever manufactured and in 2005 was designated by the World Health Organization (WHO) as an essential public health resource for all nations (*WHO Model List of Essential Medicines. World Health Organization. 2005*). Moreover, despite its potential to exacerbate bronchoconstriction, it has known clinical utility in preventing asthma-associated morbidity in children (Mazur 2002), raising the possibility that use of ibuprofen as a reference for these studies might yield new insight into the ability of the drug to complement existing strategies for management of asthma.

CONCLUSIONS:

Results of the present study suggest that a product based on the combined activity of ASX, EGb761 and vitamin C would be of substantial benefit for a large percentage of the World's population at risk of or suffering from chronic inflammatory disease. The product would be as potent as ibuprofen, but could be consumed prophylactically for general health to decrease the overall risk of chronic inflammatory disease; and would also be valuable for augmenting the effects of other therapies for persons who become ill.

ASX and ginkgo extracts are minimally toxic (Bagnis et al. 1996; Haines et al. 2000; Mahmoud et al. 2002; Mahmoud et al. 2004; Wang, Willen, and Wadstrom 2000) and are marketed in the U.S. without prescription as components of food or food supplements. The present study demonstrates that oral administration of these phytonutrients to asthmatic animals along with vitamin C, significantly improved major indicators of asthma severity. Specifically, the therapeutic agents reduced lung infiltration

1
2
3 by polymorphonuclear leukocytes; and increased levels of cyclic nucleotides in lung
4
5 tissue. Both effects correlate strongly with reduced inflammation and improved prognosis
6
7 in asthma (Busse 1998; Hai 2007; Hamad et al. 2003; Wenzel 1996). These observations
8
9 suggest that the phytochemical formulations evaluated here, have potential to decrease
10
11 risk of, and improve therapy for a diverse spectrum of inflammatory pathologies and
12
13 could greatly improve quality-of-life for millions of people Worldwide.
14
15
16
17
18
19

20 **ACKNOWLEDGMENT**

21
22 The authors acknowledge the efforts of Stephanie C. Fox, President, QueenBeeEdit in
23
24 formatting proofreading and editing this manuscript in preparation for publication. This
25
26 study was supported by grants from OTKA 72315, OTKA 78223, GVOP-3.2.1.-2004-04-
27
28 0269/3.0, TAMOP-4.2.2-08/1-2008-0007, and TAMOP-4.2.1.B-09/1.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

- Asako H, Kubes P, Baethge BA, Wolf RE, and Granger DN. 1992. Reduction of leukocyte adherence and emigration by cyclosporine and L683,590 (FK506) in postcapillary venules. *Transplantation* **54**: 686-90.
- Bagnis C, Deray G, Dubois M, Pirotzky E, Jacquiaud C, Baghos W, Aupetit B, Braquet P, and Jacobs C. 1996. Prevention of cyclosporin nephrotoxicity with a platelet-activating factor (PAF) antagonist. *Nephrol Dial Transplant* **11**: 507-13.
- Bjarnason I. 2007. Ibuprofen and gastrointestinal safety: a dose-duration-dependent phenomenon. *J R Soc Med* **100 Suppl 48**: 11-4.
- Brochet D, Chermat R, DeFeudis FV, and Drieu K. 1999. Effects of single intraperitoneal injections of an extract of Ginkgo biloba (EGb 761) and its terpene trilactone constituents on barbital-induced narcosis in the mouse. *Gen Pharmacol* **33**: 249-56.
- Busse WW. 1998. Leukotrienes and inflammation. *Am J Respir Crit Care Med* **157**: S210-3; discussion S247-8.
- Calabresse C, Nguer MC, Pellegrini O, Benveniste J, Richard Y, and Thomas Y. 1992. Induction of high-affinity paf receptor expression during T cell activation. *Eur J Immunol* **22**: 1349-55.

- 1
2
3 Chan CC, Reid CM, Aw TJ, Liew D, Haas SJ, and Krum H. 2009. Do COX-2 inhibitors
4 raise blood pressure more than nonselective NSAIDs and placebo? An updated
5 meta-analysis. *J Hypertens* **27**: 2332-41.
6
7
8
9
10
11 Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, and Simmons
12 DL. 2002. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and
13 other analgesic/antipyretic drugs: cloning, structure, and expression. *Proc Natl*
14 *Acad Sci U S A* **99**: 13926-31.
15
16
17
18
19
20
21
22 Dajani EZ, and Islam K. 2008. Cardiovascular and gastrointestinal toxicity of selective
23 cyclo-oxygenase-2 inhibitors in man. *J Physiol Pharmacol* **59 Suppl 2**: 117-33.
24
25
26
27
28 El H, II, Malik SM, Alwakeel HR, Shaikh OS, Sasatomi E, and Kandil HM. 2009.
29 Celecoxib-induced cholestatic liver failure requiring orthotopic liver
30 transplantation. *World J Gastroenterol* **15**: 3937-9.
31
32
33
34
35
36
37 Evans EG. 2003. Drug synergies and the potential for combination therapy in
38 onychomycosis. *Br J Dermatol* **149 Suppl 65**: 11-3.
39
40
41
42
43 Fan L, Vonshak A, Zarka A, and Boussiba S. 1998. Does astaxanthin protect
44 Haematococcus against light damage? *Z Naturforsch C* **53**: 93-100.
45
46
47
48
49 Feldman HA, and McMahon TA. 1983. The 3/4 mass exponent for energy metabolism is
50 not a statistical artifact. *Respir Physiol* **52**: 149-63.
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Grosser T. 2009. Variability in the response to cyclooxygenase inhibitors: toward the individualization of nonsteroidal anti-inflammatory drug therapy. *J Investig Med* **57**: 709-16.

Hai CM. 2007. Airway smooth muscle cell as therapeutic target of inflammation. *Curr Med Chem* **14**: 67-76.

Haines DD, Bak I, Ferdinandy P, Mahmoud FF, Al-Harbi SA, Blasig IE, and Tosaki A. 2000. Cardioprotective effects of the calcineurin inhibitor FK506 and the PAF receptor antagonist and free radical scavenger, EGb 761, in isolated ischemic/reperfused rat hearts. *J Cardiovasc Pharmacol* **35**: 37-44.

Hamad AM, Clayton A, Islam B, and Knox AJ. 2003. Guanylyl cyclases, nitric oxide, natriuretic peptides, and airway smooth muscle function. *Am J Physiol Lung Cell Mol Physiol* **285**: L973-83.

Harrington LS, Lucas R, McMaster SK, Moreno L, Scadding G, Warner TD, and Mitchell JA. 2008. COX-1, and not COX-2 activity, regulates airway function: relevance to aspirin-sensitive asthma. *FASEB J* **22**: 4005-10.

Hawkey CJ. 2001. COX-1 and COX-2 inhibitors. *Best Pract Res Clin Gastroenterol* **15**: 801-20.

Kakuta H, Zheng X, Oda H, Harada S, Sugimoto Y, Sasaki K, and Tai A. 2008. Cyclooxygenase-1-selective inhibitors are attractive candidates for analgesics that

1
2
3 do not cause gastric damage. design and in vitro/in vivo evaluation of a
4
5 benzamide-type cyclooxygenase-1 selective inhibitor. *J Med Chem* **51**: 2400-11.
6
7

8
9 Kang JO, Kim SJ, and Kim H. 2001. Effect of astaxanthin on the hepatotoxicity, lipid
10 peroxidation and antioxidative enzymes in the liver of CCl₄-treated rats. *Methods*
11
12 *Find Exp Clin Pharmacol* **23**: 79-84.
13
14

15
16
17 Kirkham P, and Rahman I. 2006. Oxidative stress in asthma and COPD: antioxidants as a
18 therapeutic strategy. *Pharmacol Ther* **111**: 476-94.
19
20

21
22
23 Kose F, Besen A, Paydas S, Balal M, Gonlusen G, Inal T, Dogan A, and Kibar M. 2009.
24 Effects of selective Cox-2 inhibitor, rofecoxib, alone or combination with
25 furosemide on renal functions and renal Cox-2 expression in rats. *Clin Exp*
26
27 *Nephrol*.
28
29
30
31

32
33
34 Kurashige M, Okimasu E, Inoue M, and Utsumi K. 1990. Inhibition of oxidative injury of
35 biological membranes by astaxanthin. *Physiol Chem Phys Med NMR* **22**: 27-38.
36
37

38
39
40 Mahmoud FF, Abul HT, Haines DD, Abal AT, and Wise JA. 2002. In vitro effects of
41 ginkgolide B combined with cyclosporin A on T-lymphocyte activation and IL-5
42 expression in peripheral blood mononuclear cells from asthmatic subjects.
43
44
45
46
47 *Transplant Proc* **34**: 2958-61.
48

49
50 Mahmoud FF, Haines DD, Abul HT, Abal AT, Onadeko BO, and Wise JA. 2004. In vitro
51 effects of astaxanthin combined with ginkgolide B on T lymphocyte activation in
52
53
54
55
56
57
58
59
60

1
2
3 peripheral blood mononuclear cells from asthmatic subjects. *J Pharmacol Sci* **94**:
4
5 129-36.
6
7

8
9 Mazur LJ. 2002. Ibuprofen was more protective against asthma morbidity than
10
11 acetaminophen in asthmatic children with fever. *ACP J Club* **137**: 108.
12
13

14
15 Moore N. 2007. Ibuprofen: a journey from prescription to over-the-counter use. *J R Soc*
16
17 *Med* **100 Suppl 48**: 2-6.
18
19

20
21 Rao P, and Knaus EE. 2008. Evolution of nonsteroidal anti-inflammatory drugs
22
23 (NSAIDs): cyclooxygenase (COX) inhibition and beyond. *J Pharm Pharm Sci* **11**:
24
25 81s-110s.
26
27

28
29 Ray A. 2009. Beyond debacle and debate: developing solutions in drug safety. *Nat Rev*
30
31 *Drug Discov* **8**: 775-9.
32
33

34
35 Santing RE, Meurs H, van der Mark TW, Remie R, Oosterom WC, Brouwer F, and
36
37 Zaagsma J. 1992. A novel method to assess airway function parameters in
38
39 chronically instrumented, unrestrained guinea-pigs. *Pulm Pharmacol* **5**: 265-72.
40
41

42
43 Saponara R, and Bosisio E. 1998. Inhibition of cAMP-phosphodiesterase by biflavones of
44
45 Ginkgo biloba in rat adipose tissue. *J Nat Prod* **61**: 1386-7.
46
47

48
49 Sasakawa Y, Sakuma S, Higashi Y, Sasakawa T, Amaya T, and Goto T. 2000. FK506
50
51 suppresses neutrophil chemoattractant production by peripheral blood
52
53 mononuclear cells. *Eur J Pharmacol* **403**: 281-8.
54
55
56
57
58
59
60

- 1
2
3 Soberman RJ, and Christmas P. 2003. The organization and consequences of eicosanoid
4
5 signaling. *J Clin Invest* **111**: 1107-13.
6
7
8
9 Umetsu DT, McIntire JJ, Akbari O, Macaubas C, and DeKruyff RH. 2002. Asthma: an
10
11 epidemic of dysregulated immunity. *Nat Immunol* **3**: 715-20.
12
13
14 Underwood DC, Osborn RR, Novak LB, Matthews JK, Newsholme SJ, Udem BJ, Hand
15
16 JM, and Torphy TJ. 1993. Inhibition of antigen-induced bronchoconstriction and
17
18 eosinophil infiltration in the guinea pig by the cyclic AMP-specific
19
20 phosphodiesterase inhibitor, rolipram. *J Pharmacol Exp Ther* **266**: 306-13.
21
22
23
24
25
26 Wallace JL. 1999. Distribution and expression of cyclooxygenase (COX) isoenzymes,
27
28 their physiological roles, and the categorization of nonsteroidal anti-inflammatory
29
30 drugs (NSAIDs). *Am J Med* **107**: 11S-16S; discussion 16S-17S.
31
32
33
34 Wang X, Willen R, and Wadstrom T. 2000. Astaxanthin-rich algal meal and vitamin C
35
36 inhibit *Helicobacter pylori* infection in BALB/cA mice. *Antimicrob Agents*
37
38 *Chemother* **44**: 2452-7.
39
40
41
42 Warner TD, and Mitchell JA. 2002. Cyclooxygenase-3 (COX-3): filling in the gaps
43
44 toward a COX continuum? *Proc Natl Acad Sci U S A* **99**: 13371-3.
45
46
47
48 Wenzel-Seifert K, and Seifert R. 1993. Partial inhibition of human neutrophil activation
49
50 by FK-506 at supratherapeutic concentrations. *Naunyn Schmiedebergs Arch*
51
52 *Pharmacol* **348**: 7-13.
53
54
55
56
57
58
59
60

1
2
3 Wenzel SE. 1996. Abnormalities of cell and mediator levels in bronchoalveolar lavage
4 fluid of patients with mild asthma. *J Allergy Clin Immunol* **98**: S17-21; discussion
5 S33-40.
6
7
8
9

10
11 *WHO Model List of Essential Medicines. World Health Organization. 2005* [cited.
12 Available from http://whqlibdoc.who.int/hq/2005/a87017_eng.pdf
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

1
2
3 **Figure 1. Magnitude of inflammation-associated responses in animals treated with**
4 **phytonutrients or ibuprofen: Bronchoalveolar lavage (BAL) fluid content of**
5 **eosinophils.**

6
7 OA-sensitized Guinea pig groups (6 animals in each group) treated as described
8 previously with 0-200 mg/kg astaxanthin (ASX), 0-100 mg/kg *Ginkgo biloba* leaf extract
9 (EGb761), 0-400 mg/kg vitamin C (VitC), combinations of ASX, Ginkgo and vitamin C
10 and 0-1,000 mg/kg ibuprofen (IBP). Data shown are restricted to outcomes from
11 treatment groups receiving the lowest dose of each product resulting in values of each
12 inflammation indicator significantly different ($p < 0.05$) than results from asthmatic, drug-
13 free control animals.
14

15
16 * Inflammation indicator magnitudes significantly different ($p < 0.05$) than results from asthmatic, drug-free
17 control animals.
18

19
20 **Figure 2. Magnitude of inflammation-associated responses in animals treated with**
21 **phytonutrients or ibuprofen: Bronchoalveolar lavage (BAL) fluid content of**
22 **neutrophils.**

23
24 OA-sensitized Guinea pig groups (6 animals in each group) treated as described
25 previously with 0-200 mg/kg astaxanthin (ASX), 0-100 mg/kg *Ginkgo biloba* leaf extract
26 (EGb761), 0-400 mg/kg vitamin C (VitC), combinations of ASX, Ginkgo and vitamin C
27 and 0-1,000 mg/kg ibuprofen (IBP). Data shown is restricted to outcomes from treatment
28 groups receiving the lowest dose of each product resulting in values of each inflammation
29 indicator significantly different ($p < 0.05$) than results from asthmatic, drug-free control
30 animals.
31

32
33 * Inflammation indicator magnitudes significantly different ($p < 0.05$) than results from asthmatic, drug-free
34 control animals.
35

36
37 **Figure 3. Magnitude of inflammation-associated responses in animals treated with**
38 **phytonutrients or ibuprofen: Bronchoalveolar lavage (BAL) fluid content of**
39 **macrophages.**

40
41 OA-sensitized Guinea pig groups (6 animals in each group) treated as described
42 previously with 0-200 mg/kg astaxanthin (ASX), 0-100 mg/kg *Ginkgo biloba* leaf extract
43 (EGb761), 0-400 mg/kg vitamin C (VitC), combinations of ASX, Ginkgo and vitamin C
44 and 0-1,000 mg/kg ibuprofen (IBP). Data shown is restricted to outcomes from treatment
45 groups receiving the lowest dose of each product resulting in values of each inflammation
46 indicator significantly different ($p < 0.05$) than results from asthmatic, drug-free control
47 animals.
48

49
50 * Inflammation indicator magnitudes significantly different ($p < 0.05$) than results from asthmatic, drug-free
51 control animals.
52

53
54 **Figure 4. Magnitude of inflammation-associated responses in animals treated with**
55 **phytonutrients or ibuprofen: enhanced lung tissue content of cAMP.**

56
57 OA-sensitized Guinea pig groups (6 animals in each group) treated as described
58 previously with 0-200 mg/kg astaxanthin (ASX), 0-100 mg/kg *Ginkgo biloba* leaf extract
59 (EGb761), 0-400 mg/kg vitamin C (VitC), combinations of ASX, Ginkgo and vitamin C
60

1
2
3 and 0-1,000 mg/kg ibuprofen (IBP). Data shown is restricted to outcomes from treatment
4 groups receiving the lowest dose of each product resulting in values of each inflammation
5 indicator significantly different ($p<0.05$) than results from asthmatic, drug-free control
6 animals.
7

8
9 * Inflammation indicator magnitudes significantly different ($p<0.05$) than results from asthmatic, drug-free
10 control animals.
11

12
13 **Figure 5. Magnitude of inflammation-associated responses in animals treated with
14 phytonutrients or ibuprofen: enhanced lung tissue content of cGMP.**

15 OA-sensitized Guinea pig groups (6 animals in each group) treated as described
16 previously with 0-200 mg/kg astaxanthin (ASX), 0-100 mg/kg *Ginkgo biloba* leaf extract
17 (EGb761), 0-400 mg/kg vitamin C (VitC), combinations of ASX, Ginkgo and vitamin C
18 and 0-1,000 mg/kg ibuprofen (IBP). Data shown is restricted to outcomes from treatment
19 groups receiving the lowest dose of each product resulting in values of each inflammation
20 indicator significantly different ($p<0.05$) than results from asthmatic, drug-free control
21 animals.
22

23
24 * Inflammation indicator magnitudes significantly different ($p<0.05$) than results from asthmatic, drug-free
25 control animals.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1.
Bronchoalveolar lavage (BAL) eosinophil content




Figure 2.
Bronchoalveolar lavage (BAL) Neutrophil content




Figure 3.
Bronchoalveolar lavage (BAL) macrophage content




Figure 4.
Lung Tissue cAMP content




Figure 5.
Lung Tissue cGMP content




Table 1. Lung inflammation-associated parameter values in treatment groups (basic data).

Numbers of inflammatory cells in bronchoalveolar lavage (BAL) fluid and levels of the cyclic nucleotides cAMP and cGMP in lung tissue were measured in ovalbumin (OA)-sensitized guinea pigs, segregated into dosage groups of 6 animals each and administered feed containing the following supplements (referred to here as “drugs): astaxanthin (1A), *Ginkgo biloba* leaf extract (EGb761) (1B), vitamin C (1C), selected combinations of each (1D), or ibuprofen (1E), daily for 26 days. Two groups, designated as drug-free controls were given feed without phytochemicals or ibuprofen. One of these two control groups was exposed to vehicle aerosol (nebulized saline) only, without OA challenge and is designated below: “OA-neg, non-asthma, no drugs”. The other control group which received an OA challenge is designated below: “OA+ asthma+, no drugs”. Twentyfour hours following the 26-day drug treatment period, asthma was induced by OA inhalation, animals were sacrificed and BAL inflammatory cell levels and lung tissue cyclic nucleotide content was measured in each animal. Data is reported as mean \pm standard error of means (SEM) of measurements taken in the 6 animals constituting each treatment group.

1A. Astaxanthin (ASX)-treated animals.

| Cohort size: n = 6 | OA-neg non-asthma no drugs | OA+ asthma+ no drugs | OA+ 5mg/kg ASX | OA+ 10mg/kg ASX | OA+ 30mg/kg ASX | OA+ 100mg/kg ASX | OA+ 200mg/kg ASX |
|--|----------------------------------|----------------------------|----------------------|-----------------------|-----------------------|------------------------|------------------------|
| Eosinophils (cells x 10 ⁶ /animal). | 1.4 \pm 0.2 | 5.4 \pm 0.8 | 5.0 \pm 0.7 | 4.6 \pm 0.6 | 3.1 \pm 0.5* | 2.4 \pm 0.6* | 2.3 \pm 0.5* |
| Neutrophils (cells x 10 ⁵ /animal) | 1.1 \pm 0.3 | 5.8 \pm 0.7 | 5.4 \pm 0.8 | 5.1 \pm 0.6 | 3.3 \pm 0.8* | 2.4 \pm 0.5* | 2.0 \pm 0.4* |
| Macrophages (cells x 10 ⁶ /animal) | 1.7 \pm 0.5 | 9.9 \pm 1.1 | 9.6 \pm 1.0 | 8.0 \pm 0.8 | 3.7 \pm 0.7* | 2.70 \pm 0.7* | 2.6 \pm 0.5* |
| cAMP pMol/mg lung protein | 10.9 \pm 0.98 | 6.7 \pm 0.58 | 6.9 \pm 0.5 | 8.1 \pm 0.8 | 9.6 \pm 0.8* | 12.6 \pm 0.8* | 12.1 \pm 0.5* |
| cGMP pMol/mg lung protein | 2.6 \pm 0.26 | 1.1 \pm 0.17 | 1.2 \pm 0.1 | 1.4 \pm 0.1 | 1.8 \pm 0.3* | 2.8 \pm 0.3* | 2.7 \pm 0.2* |

1B. *Ginkgo biloba* (EGb761)-treated animals.

| Cohort size: n = 6 | OA-neg non- asthma no drugs | OA+ asthma+ no drugs | OA+ 5mg/kg EGb761 | OA+ 10mg/kg EGb761 | OA+ 30mg/kg EGb761 | OA+ 100mg/kg EGb761 |
|--|-----------------------------------|----------------------------|-------------------------|--------------------------|--------------------------|---------------------------|
| Eosinophils (cells x 10 ⁶ /animal). | 1.4 \pm 0.2 | 5.4 \pm 0.8 | 5.1 \pm 0.9 | 5.0 \pm 0.8 | 3.5 \pm 0.8* | 3.1 \pm 0.5* |
| Neutrophils (cells x 10 ⁵ /animal) | 1.1 \pm 0.3 | 5.8 \pm 0.7 | 5.6 \pm 0.6 | 5.4 \pm 0.6 | 3.5 \pm 0.7* | 3.3 \pm 0.6* |
| Macrophages (cells x 10 ⁶ /animal) | 1.7 \pm 0.5 | 9.9 \pm 1.1 | 9.8 \pm 1.1 | 9.4 \pm 1.1 | 4.9 \pm 1.5* | 4.2 \pm 0.6* |
| cAMP pMol/mg lung protein | 10.9 \pm 0.98 | 6.7 \pm 0.58 | 6.9 \pm 0.6 | 8.0 \pm 0.9 | 9.8 \pm 0.7* | 12.0 \pm 1.3* |
| cGMP pMol/mg lung protein | 2.6 \pm 0.26 | 1.1 \pm 0.17 | 1.1 \pm 0.2 | 1.1 \pm 0.2 | 1.5 \pm 0.2* | 1.8 \pm 0.3* |

1C. Vitamin C-treated animals.

| Cohort size: n = 6 | OA-neg non- asthma no drugs | OA+ asthma+ no drug | OA+ 50mg/kg Vit. C | OA+ 100mg/kg Vit. C | OA+ 200mg/kg Vit. C | OA+ 400mg/kg Vit. C |
|--|-----------------------------------|---------------------------|--------------------------|---------------------------|---------------------------|---------------------------|
| Eosinophils (cells x 10 ⁶ /animal). | 1.4±0.2 | 5.4±0.8 | 5.5±0.5 | 5.5±0.8 | 4.8±1.1 | 3.5±0.9* |
| Neutrophils (cells x 10 ⁵ /animal) | 1.1±0.3 | 5.8±0.7 | 5.4±0.6 | 5.6±0.8 | 5.0±0.8 | 4.7±0.9 |
| Macrophages (cells x 10 ⁶ /animal) | 1.7±0.5 | 9.9±1.1 | 9.5±0.9 | 9.8±0.9 | 9.2 ±0.8 | 7.2±1.5* |
| cAMP pMol/mg lung protein | 10.9±0.98 | 6.7±0.58 | 6.8±0.5 | 7.1±0.8 | 7.9±0.9 | 7.9±0.8 |
| cGMP pMol/mg lung protein | 2.6±0.26 | 1.1±0.17 | 1.1±0.2 | 1.0±0.2 | 1.2±0.2 | 1.5±0.2* |

1D. Combination treatments: Animals simultaneously administered astaxanthin, *Ginkgo biloba* (EGb761) and vitamin C

| Cohort size: n = 6 | OA-neg non- asthma no drugs | OA+ asthma+ no drug | OA+ 5 mg/kg ASX + 5 mg/kg EGb761 + 50 mg/kg Vit C | OA+ 10 mg/kg ASX + 10 mg/kg EGb761 + 200 mg/kg Vit C | OA+ 30 mg/kg ASX + 30 mg/kg EGb761 + 400 mg/kg Vit C |
|--|-----------------------------------|---------------------------|--|---|---|
| Eosinophils (cells x 10 ⁶ /animal). | 1.4±0.2 | 5.4±0.8 | 5.07±0.63 | 3.44±0.84* | 2.95±0.62* |
| Neutrophils (cells x 10 ⁵ /animal) | 1.1±0.3 | 5.8±0.7 | 5.27±0.74 | 3.65±0.65* | 2.60±0.69* |
| Macrophages (cells x 10 ⁶ /animal) | 1.7±0.5 | 9.9±1.1 | 9.40±0.96 | 5.78±1.18* | 2.98±0.71* |
| cAMP pMol/mg lung protein | 10.9±0.98 | 6.7±0.58 | 7.17± 0.61 | 9.28±0.94* | 13.00±0.76* |
| cGMP pMol/mg lung protein | 2.6±0.26 | 1.1±0.17 | 1.17± 0.19 | 2.09±0.48* | 2.84±0.28* |

1E. Ibuprofen-treated animals.

| Cohort size: n = 6 | Asthma-free control (OA neg) | OA+ asthma, no drug | OA+ IB 10mg/kg | OA+ IB 100mg/kg | OA+ IB 500mg/kg | OA+ IB 1000mg/kg |
|--|------------------------------------|---------------------------|----------------------|-----------------------|-----------------------|------------------------|
| Eosinophils (cells x 10 ⁶ /animal). | 1.4±0.2 | 5.4±0.8 | 5.4±0.8 | 4.7±0.6 | 3.0±0.8* | 2.9±0.5* |
| Neutrophils (cells x 10 ⁵ /animal) | 1.1±0.3 | 5.8±0.7 | 5.7±0.7 | 5.0±0.7 | 3.1±0.9* | 3.1±0.5* |
| Macrophages (cells x 10 ⁶ /animal) | 1.7±0.5 | 9.9±1.1 | 9.5±0.8 | 9.0±1.3 | 4.7±1.3* | 4.3±0.9* |
| cAMP pMol/mg lung protein | 10.9±0.98 | 6.7±0.58 | 7.1±0.6 | 7.3±0.9 | 8.2±0.8* | 8.1±0.9* |
| cGMP pMol/mg lung protein | 2.6±0.26 | 1.1±0.17 | 1.1±0.2 | 1.1±0.2 | 1.4±0.2 | 1.6±0.2* |

*p<0.05 compared to corresponding values of OA antigen-challenged, asthmatic drug-free control group.